Giracodazole

Giracodazole

SCHEMBL1228801

NC[C@H](Cl)[C@@H](O)c1cnc(N)[nH]1

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 1/20 0.31
MASP2 O00187 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Giracodazole SCHEMBL29479373 1.00 AOC3 (0.31) AOC3MASP2
Giracodazole SCHEMBL9862352 0.66
SCHEMBL3194799 0.58 SLC6A2 (0.59) AOC3
SCHEMBL7328921 0.57
SCHEMBL216691 0.57
SCHEMBL5156890 0.55 CYP2D6 (0.39) AOC3MASP2
SCHEMBL12598153 0.54 AOC3 (0.48) AOC3
SCHEMBL4411566 0.54
SCHEMBL14941638 0.53
SCHEMBL10588740 0.53 TAAR1 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2961730-A2 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XenoPort, Inc. (US) 2016-01-06 EP claimed
US-20150158809-A9 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2015-06-11 US claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
WO-2014134005-A2 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2014-09-04 WO claimed
US-20140243544-A1 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2014-08-28 US claimed
CN-101486668-B Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof XENOPORT INC 2014-07-02 CN claimed
US-8062870-B2 Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs XENOPORT, INC. (US) 2011-11-22 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
CN-1850042-A Anticancer slow release agent carrying platinum medicine and its synergist SHUAIHUA MEDICINE SCIENCE TECH (CN) 2006-10-25 CN claimed
CN-1846689-A Slow-released anticancer prepn containing taxane and its synergist JINAN KANGQUAN MEDICINE SCI TE (CN) 2006-10-18 CN claimed
CN-1846670-A Anticancer implant JINAN SHUAIHUA MEDICINE SCI TE (CN) 2006-10-18 CN claimed
CN-1846680-A Methotrexate sustained-release injection JINAN SHUAIHUA MEDICINE SCI TE (CN) 2006-10-18 CN claimed
CN-1839843-A Fluorouracil slow release injection JINAN SHUAIHUA MEDICINE TECHNO (CN) 2006-10-04 CN claimed
CN-1824314-A Slow-release agent containing hormone anticancer medicine JINAN KANGQUAN MEDICINE SCI & (CN) 2006-08-30 CN claimed
CN-1748671-A Slow releasing injection containing anti-mitosis medicine KONG QINGZHONG (CN) 2006-03-22 CN claimed
CN-1733301-A Anticancer implantation agent KONG QINGZHONG (CN) 2006-02-15 CN claimed
CN-1679950-A Anticarcinogenic internal implant agent LANJIN BIOLOG ENGINEERING CO L (CN) 2005-10-12 CN claimed
CN-1660436-A Anticancer combination of medication LANJIN BIOLOG ENGINEERING CO L (CN) 2005-08-31 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150158809-A9 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS CPS1, CA7, NAAA AOC3 357/4885MASP2 3673/4885
US-20140243544-A1 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS CPS1, CA7, NAAA AOC3 357/4885MASP2 3673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.